Tris launches promethazine and codeine syrup
Tris Pharma has announced the introduction of its promethazine and codeine syrup (promethazine HCl and codeine phosphate oral solution. The product is manufactured at the company’s facility in Monmouth Junction, N.J.
Tris’ promethazine and codeine syrup will be available in 16-oz. bottles in dosage strengths of 6.25 mg and 10 mg per 5-ml oral solution. The drug is indicated for temporary relief of coughs and uppers respiratory system associated with allergies or the common cold in patients 18 years of age and older. The drug’s market size was for the 12 months ended December 2017 was roughly $8 million, according to IQVIA data.
Tris’ promethazine and codeine syrup will be available in 16-oz. bottles in dosage strengths of 6.25 mg and 10 mg per 5-ml oral solution. The drug is indicated for temporary relief of coughs and uppers respiratory system associated with allergies or the common cold in patients 18 years of age and older. The drug’s market size was for the 12 months ended December 2017 was roughly $8 million, according to IQVIA data.